Neobiomics announced today an agreement with IPS Pharma, a UK-based pharmaceutical services company, to provide patients in the UK access to Proprems® – a high grade probiotics product.
Under the agreement, IPS Pharma will store, manage and distribute ProPrems® from its UK based MHRA approved facility.
This collaboration will ensure patients secured and easy access to ProPrems® in the UK, even in the event of a hard Brexit.
– We are very glad to work with IPS Pharma to help us provide ProPrems® for neonatal care services in the UK. Our mission and vision around ProPrems® goes beyond any political turbulence, says Stefan Johansson, founder and CEO of Neobiomics.
For more information about ProPrems®